Q1 / Q2: CFR 320 may be of some help [Regulatives / Guidelines]

posted by luvblooms  – India, 2015-05-04 08:55 (3643 d 09:14 ago) – Posting: # 14747
Views: 10,511

Hi John


❝ Does anyone know if there is some kind of FDA guidance on Q1 and Q2? I searched around and only find bits and pieces of information...


As of now even I am not aware of any specific Q1/Q2 guidance but there are sufficient information available in CFR's.

Do check these links
  1. Excipients: A Regulatory Support Prospective: Many CFR links are given for Solution, opthalmics and injections

  2. Criteria for waiver of evidence of in vivo bioavailability or bioequivalence.

  3. 21 CFR 320.22 - Criteria for waiver of evidence of in vivo bioavailability or bioequivalence

Hope this would be of some help!!!

~A happy Soul~

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,669 registered users;
25 visitors (0 registered, 25 guests [including 5 identified bots]).
Forum time: 18:09 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5